IDiyas

For the Inventor, By the Inventor

Harlow, United Kingdom

Michael Lainchbury

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 8.6

ph-index = 5

Forward Citations = 33(Granted Patents)


Company Filing History:

goldMedal10 out of 3,221 
 
Genentech, Inc.
 patents
silverMedal6 out of 262 
 
Cancer Research Technology Limited
 patents

Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),
2. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),
3. 12208088 - Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof (2025-01-28),
4. 11944606 - Azaindoles as inhibitors of HPK1 (2024-04-02),
5. 11787792 - 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof (2023-10-17),
6. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),
7. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),
8. 10952995 - Azaindoles as inhibitors of HPK1 (2021-03-23),
9. 10407424 - Naphthyridines as inhibitors of HPK1 (2019-09-10),
10. 10259806 - 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof (2019-04-16),
11. 9951064 - Azaindazole compounds as inhibitors of T790M containing EGFR mutants (2018-04-24),
12. 9890152 - Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants (2018-02-13),
13. 9765059 - 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use (2017-09-19),
14. 9663503 - 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof (2017-05-30),
15. 9403797 - 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use (2016-08-02),

Title: Michael Lainchbury: Innovator in Isoquinoline and Naphthyridine Compounds

Introduction

Michael Lainchbury is a prominent inventor based in Harlow, GB. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on isoquinoline and naphthyridine compounds. With a total of 16 patents to his name, Lainchbury's inventions are paving the way for advancements in treating various health disorders.

Latest Patents

Among his latest patents, Lainchbury has developed isoquinoline compounds that serve as inhibitors of HPK1 (hematopoietic kinase 1). These compounds are particularly useful in treating HPK1-dependent disorders and enhancing immune responses. His work also includes methods for inhibiting HPK1, treating related disorders, and preparing these isoquinoline compounds. Additionally, he has worked on naphthyridine compounds, further expanding the scope of his research and its applications in medicine.

Career Highlights

Throughout his career, Lainchbury has been associated with notable companies such as Genentech, Inc. and Cancer Research Technology Limited. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Lainchbury has collaborated with esteemed colleagues, including Bryan K Chan and Timothy Heffron. These partnerships have enriched his research and fostered innovation in the development of new therapeutic compounds.

Conclusion

Michael Lainchbury's contributions to the field of medicinal chemistry through his patents on isoquinoline and naphthyridine compounds highlight his role as a key innovator. His work continues to influence the treatment of HPK1-dependent disorders and enhance immune responses.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…